Mylan N.V. (NASDAQ:MYL)‘s stock had its “buy” rating restated by investment analysts at Mizuho in a research report issued on Tuesday. They presently have a $37.00 target price on the stock. Mizuho’s price objective indicates a potential downside of 4.93% from the stock’s previous close.

A number of other brokerages also recently issued reports on MYL. Wells Fargo & Company set a $32.00 price target on shares of Mylan N.V. and gave the stock a “hold” rating in a research report on Wednesday, October 4th. Morgan Stanley boosted their price target on shares of Mylan N.V. from $36.00 to $39.00 and gave the stock an “equal weight” rating in a research report on Friday, October 6th. Cantor Fitzgerald set a $34.00 price target on shares of Mylan N.V. and gave the stock a “hold” rating in a research report on Wednesday, August 9th. BMO Capital Markets restated a “buy” rating and issued a $45.00 price target on shares of Mylan N.V. in a research report on Friday, September 29th. Finally, ValuEngine upgraded shares of Mylan N.V. from a “hold” rating to a “buy” rating in a research report on Monday, October 2nd. One research analyst has rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the stock. The company presently has a consensus rating of “Buy” and a consensus price target of $41.21.

Shares of Mylan N.V. (MYL) traded up 1.17% during midday trading on Tuesday, reaching $38.92. 5,906,255 shares of the company’s stock traded hands. Mylan N.V. has a 52-week low of $29.39 and a 52-week high of $45.87. The stock has a 50-day moving average price of $34.56 and a 200-day moving average price of $36.23. The stock has a market cap of $20.87 billion, a P/E ratio of 31.46 and a beta of 1.30.

Mylan N.V. (NASDAQ:MYL) last issued its quarterly earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of $1.18 by ($0.08). The firm had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3 billion. Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The firm’s revenue for the quarter was up 15.7% on a year-over-year basis. During the same quarter last year, the firm posted $1.16 EPS. Analysts forecast that Mylan N.V. will post $4.58 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Mylan N.V. (MYL) Stock Rating Reaffirmed by Mizuho” was reported by American Banking News and is owned by of American Banking News. If you are reading this piece on another domain, it was illegally stolen and reposted in violation of United States and international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/24/mylan-n-v-myl-stock-rating-reaffirmed-by-mizuho.html.

A number of hedge funds have recently made changes to their positions in the business. TrueNorth Inc. increased its stake in Mylan N.V. by 13.7% during the 3rd quarter. TrueNorth Inc. now owns 32,422 shares of the company’s stock valued at $1,017,000 after purchasing an additional 3,898 shares in the last quarter. Nationwide Fund Advisors increased its stake in Mylan N.V. by 4.8% during the 3rd quarter. Nationwide Fund Advisors now owns 461,279 shares of the company’s stock valued at $14,470,000 after purchasing an additional 21,184 shares in the last quarter. Whittier Trust Co. increased its stake in Mylan N.V. by 3.4% during the 3rd quarter. Whittier Trust Co. now owns 77,479 shares of the company’s stock valued at $2,429,000 after purchasing an additional 2,554 shares in the last quarter. Gilman Hill Asset Management LLC increased its stake in Mylan N.V. by 9.9% during the 3rd quarter. Gilman Hill Asset Management LLC now owns 14,527 shares of the company’s stock valued at $456,000 after purchasing an additional 1,310 shares in the last quarter. Finally, State Treasurer State of Michigan increased its stake in Mylan N.V. by 7.4% during the 3rd quarter. State Treasurer State of Michigan now owns 162,709 shares of the company’s stock valued at $5,104,000 after purchasing an additional 11,200 shares in the last quarter. Institutional investors and hedge funds own 71.98% of the company’s stock.

About Mylan N.V.

Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.

Analyst Recommendations for Mylan N.V. (NASDAQ:MYL)

Receive News & Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related companies with MarketBeat.com's FREE daily email newsletter.